Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Comparative study of bupropion and citalopram in major depressive disorder
IRCT20190706044121N1Phase 3Completed
- Sponsor
- Golestan University of Medical Sciences
- Start
- Jan 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of bupropion and citalopram in major depressive disorder (MDD) (2 arms), sponsored by Golestan University of Medical Sciences. Primary endpoint: Primary response rate. Started Jan 2020; status: completed.
02
Drugs
bupropioncitalopram
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on IRCT20190706044121N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20190706044121N1.